The Bio-inflammation Company

Transforming Human Health Through The Restoration Of Ammonia-Oxidizing Bacteria

An evolutionary approach to restoring health

AOBiome Therapeutics is a clinical-stage therapeutics company addressing a broad range of inflammatory conditions by harnessing a single strain of class defining
Ammonia Oxidizing Bacteria (AOB).

AOBiome currently has multiple
Phase 2 clinical programs ongoing

AOBiome currently has ongoing Phase 2 clinical programs in hypertension, acne, allergic rhinitis, migraine, eczema and rosacea.


Learn More

Committed to transforming & improving human health

We believe that the restoration of the symbiotic relationship between bacteria and humans
will have a profound impact on human health.


In the News
AOBiome Doses First Patient in Phase 1b Clinical Trial of B244 for the Treatment of Pediatric Atopic Dermatitis
AOBiome Therapeutics Expands Intellectual Property Estate with Issuance of U.S. Patent for Use of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Eczema
AOBiome Therapeutics Announces Appointment of Dr. Judith Ng Cashin as Chief Medical Officer